We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Mfn4.0

Metformin Research

Mostly mechanism / observationalLimited safety

7 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Metformin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality meta-analyses and randomised trials published 1998–2022 with a typical study size of 753 participants.

Based on 7 studies · 1 meta-analysis · 3 RCTs · 806 total participants

Confidence

Moderate

By outcome

Aging & mortality
Mostly mechanism / observational6 studies
Glycemic & metabolic
Too few graded studies2 studies
Exercise interference
Too few graded studies1 study

Steady research

1 study in the last 5 years · Latest meta-analysis: 2017

199820102022

1RCTn=753 · large study1998

Intensive blood-glucose control with metformin reduced diabetes-related complications and all-cause mortality in overweight patients.

· Lancet (London, England) (1998)

UKPDS 34 randomized trial of metformin in overweight type-2 diabetics
Reduced diabetes-related endpoints and all-cause mortality vs conventional therapy
Foundational evidence for metformin's cardiovascular/mortality benefit in diabetes

2Meta-Analysis2017

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control.

Campbell, Bellman, Stephenson, Lisy · Ageing research reviews (2017)

Systematic review/meta-analysis of metformin and age-related outcomes
Reported lower all-cause mortality and reduced age-related disease
A central citation for the geroprotector hypothesis (and the TAME rationale)

View source

3Review2016

Metformin is a candidate tool to target aging via AMPK and related pathways.

Barzilai, Crandall, Kritchevsky, Espeland · Cell metabolism (2016)

Review of metformin's aging-relevant mechanisms (AMPK, insulin/IGF-1, inflammation)
Frames the TAME trial rationale
Summarizes preclinical and epidemiological support

View source

4RCTn=53 · small study2019

Metformin inhibited the mitochondrial and cardiorespiratory-fitness adaptations to aerobic exercise training in older adults.

Konopka, Laurin, Schoenberg, Reid, Castor, Wolff · Aging cell (2019)

Randomized, double-blind, placebo-controlled trial of metformin during 12 weeks of aerobic exercise training in older adults
Metformin blunted the improvement in cardiorespiratory fitness (VO2max) and skeletal-muscle mitochondrial respiration from training
Direct HUMAN evidence for the exercise-interference trade-off

View source

5RCT2018

The METAL window-of-opportunity trial investigated metformin's biological aging mechanisms in non-diabetic individuals.

Crawley, Chandra, Loda, Gillett, Cathcart, Challacombe · BMC cancer (2018)

METAL: randomized window-of-opportunity study of metformin in non-diabetic individuals
Examined metformin's effects on biological/mechanistic markers relevant to aging and cancer
Directly probes the geroprotector hypothesis in non-diabetics

View source

6Systematic Review2022

A systematic review found metformin has heterogeneous, model-dependent effects on lifespan and is most beneficial when started early.

Parish, Swindell · Aging cell (2022)

Systematic review of metformin's effects on lifespan across model organisms
Effects were heterogeneous and model/dose-dependent — not a uniform lifespan extension
Directly supports the 'contested geroprotector' framing

View source

7Review2020

Metformin attenuates several hallmarks of aging in preclinical models.

Kulkarni, Gubbi, Barzilai · Cell metabolism (2020)

Review mapping metformin's effects onto the hallmarks of aging
Covers autophagy, senescence, inflammation, and nutrient sensing
Mechanistic support for geroprotection

View source

View in Research Library

Metformin Research

Mostly mechanism / observational

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.

Metformin as a Tool to Target Aging.

Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults.

Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans: A systematic review and meta-analysis.

Benefits of Metformin in Attenuating the Hallmarks of Aging.